dryocrassin abba, a novel active substance for use against amantadine-resistance h5n1 avian influenza virus
Clicks: 321
ID: 134705
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
30.0
/100
321 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #149 of 875 articles by views in journal of magnetic resonance (san diego, calif : 1997)
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 875 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The occurrence of multi-drug resistant highly pathogenic avian influenza virus (HPAIV) strains highlights the urgent need for strategies for the prevention and control of avian influenza virus. The aim of our current study is to evaluate the antiviral activity of dryocrassin ABBA isolated from Rhizoma Dryopteridis Crassirhizomatis (RDC) against an amantadine-resistant H5N1 (A/Chicken/Hebei/706/2005) strain in a mouse model. Post inoculation with HPAIV H5N1 virus in mice, the survival rate was 87%, 80% and 60% respectively in the 33mg/kg, 18mg/kg and 12.5 mg/kg Dryocrassin ABBA-treated groups. On the other hand, the survival rate was 53% and 20%, respectively in the amantadine-treated group and untreated group. Mice administered dryocrassin ABBA or amantadine showed a significant weight increase compared to the untreated group. Moreover, 33 mg/kg and 18 mg/kg dryocrassin ABBA have decreased lung index (P>0.05) and virus loads (P<0.01) compared to the untreated group on day 7. Also, on day 7 bronchoalveolar lavage fluid pro-inflammatory cytokines (IL-6, TNF-α and IFN-γ) decreased significantly (P<0.01) while anti-inflammatory cytokines (IL-10 and MCP-1) were increased significantly (P<0.01) in the 33 mg/kg and 18 mg/kg dryocrassin ABBA-treated groups compared to the amantadine group and the untreated group. Moreover, the concentrations of IL-12 in drug-treated groups were significantly (P<0.01) lowered compared with the untreated group. Based on the above we conclude that orally administered dryocrassin ABBA provided mice protection against avian influenza virus H5N1 by inhibiting inflammation and reducing virus loads. Dryocrassin ABBA is a potential novel lead compound which had antiviral effects on amantadine-resistant avian influenza virus H5N1 infection.
| Reference Key |
ou2015frontiersdryocrassin
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Changbo Ou;Guojiang Wu;Qiang Zhang;Ningning Shi;Cheng He |
| Journal | journal of magnetic resonance (san diego, calif : 1997) |
| Year | 2015 |
| DOI |
10.3389/fmicb.2015.00592
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.